MAPT and Alzheimer disease: This approach has been validated in a study demonstrating that patients with positive CSF biomarkers of pathologic synuclein, amyloid, and tau showed a more rapid global cognitive decline compared to participants with solely LB or AD-specific biomarkers, in a cohort consisting of both MCI and dementia patients (8).